FIELD: medicine, gynecology.
SUBSTANCE: the present innovation deals with treating vaginal dryness and reproductive dysfunction in women either during or after menopause. For this purpose, it is necessary to introduce (deaminohydroxy)thoremifen or its salts or ethers at dosage ranged 25-100 mg daily either perorally or transdermally. The innovation provides efficient therapy at resistance to other types of hormonal therapy, due to multi-component impact upon disease pathogenesis.
EFFECT: higher efficiency of therapy.
8 cl, 2 dwg, 1 tbl
Authors
Dates
2006-01-20—Published
2001-05-02—Filed